Muhammed Canbaş
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Muhammed Canbaş has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Mehmet Nur Kaya
Department of Rheumatology, Faculty of Medicine, Balıkesir University, Balıkesir, Turkey
6 shared publications - Sedat Yilmaz
Rheumatology Department, Gulhane Training and Research Hospital, Ankara, Turkey
6 shared publications - Özlem Kılıç
Department of Rheumatology, Ankara Training and Research Hospital, Ankara, Türkiye
6 shared publications - Abdullah Doğan
Rheumatology Department, Gülhane Training and Research Hospital, University of Health Sciences Turkey, 38000 Ankara, Turkey
2 shared publications - Ahmet Karadağ
Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Sivas Cumhuriyet University, 58140 Sivas, Türkiye
1 shared publication - Duygu Tecer
Department of Rheumatology, University of Health Sciences, Gülhane Training and Research Hospital , Ankara
1 shared publication
Latest Publications
- 22 October 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (11) , 294
Clinical and serological features according to anti-DFS70 antibody status in undifferentiated connective tissue disease: a retrospective cross-sectional study
This study aimed to compare demographic, clinical, laboratory, and autoantibody profiles between anti-dense fine speckled 70 (DFS70)-positive and -negative patients with undifferentiated connective tissue disease (UCTD). We retrospectively analyzed 284 UCTD patients followed at a tertiary rheumatology centre between January 2017 and December 2024. Patients fulfilling established classification criteria for a defined connective tissue disease were excluded. Patients were stratified according to anti-DFS70 status. Group comparisons were performed, and the Benjamini-Hochberg procedure was applied to control the false discovery rate. A multivariable logistic regression model was additionally used to evaluate the potential confounding effect of hydroxychloroquine use. Of 284 patients, 75 (26.4%) were anti-DFS70 positive and 209 (73.6%) were negative. After false discovery rate correction, arthritis/arthralgia was more frequent in the anti-DFS70-negative group than in the positive group (81.8% vs. 61.3%, adjusted p = 0.034), as was homogeneous ANA pattern (33.5% vs. 12.0%, adjusted p = 0.034). In multivariable analysis, homogeneous ANA pattern remained associated with anti-DFS70 negativity after adjustment for hydroxychloroquine use (OR 2.71, 95% CI 1.16–6.30, p = 0.021), whereas arthritis/arthralgia did not remain statistically significant (OR 1.92, 95% CI 0.95–3.90, p = 0.071). Anti-DFS70 negativity in UCTD was associated with homogeneous ANA pattern. Clinical associations, particularly arthritis/arthralgia, should be interpreted cautiously because of potential confounding by treatment exposure. Further prospective studies are warranted to clarify the clinical significance of anti-DFS70 status in UCTD.
- 22 October 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (11) , 294
Clinical and serological features according to anti-DFS70 antibody status in undifferentiated connective tissue disease: a retrospective cross-sectional study
This study aimed to compare demographic, clinical, laboratory, and autoantibody profiles between anti-dense fine speckled 70 (DFS70)-positive and -negative patients with undifferentiated connective tissue disease (UCTD). We retrospectively analyzed 284 UCTD patients followed at a tertiary rheumatology centre between January 2017 and December 2024. Patients fulfilling established classification criteria for a defined connective tissue disease were excluded. Patients were stratified according to anti-DFS70 status. Group comparisons were performed, and the Benjamini-Hochberg procedure was applied to control the false discovery rate. A multivariable logistic regression model was additionally used to evaluate the potential confounding effect of hydroxychloroquine use. Of 284 patients, 75 (26.4%) were anti-DFS70 positive and 209 (73.6%) were negative. After false discovery rate correction, arthritis/arthralgia was more frequent in the anti-DFS70-negative group than in the positive group (81.8% vs. 61.3%, adjusted p = 0.034), as was homogeneous ANA pattern (33.5% vs. 12.0%, adjusted p = 0.034). In multivariable analysis, homogeneous ANA pattern remained associated with anti-DFS70 negativity after adjustment for hydroxychloroquine use (OR 2.71, 95% CI 1.16–6.30, p = 0.021), whereas arthritis/arthralgia did not remain statistically significant (OR 1.92, 95% CI 0.95–3.90, p = 0.071). Anti-DFS70 negativity in UCTD was associated with homogeneous ANA pattern. Clinical associations, particularly arthritis/arthralgia, should be interpreted cautiously because of potential confounding by treatment exposure. Further prospective studies are warranted to clarify the clinical significance of anti-DFS70 status in UCTD.
- Open Access
- 31 August 2026
- Published by Springer Nature in Clinical and Experimental Medicine
Association of anti-Ro52 antibody positivity with interstitial lung disease and serological features in primary Sjögren’s disease
To investigate the association of anti-Ro52 antibody positivity with interstitial lung disease (ILD), serological findings, clinical manifestations, and treatment patterns in patients with primary Sjögren’s disease (SjD). This retrospective cross-sectional study included 205 patients with SjD. Patients were classified as anti-Ro52-positive or anti-Ro52-negative. Demographic features, clinical findings, laboratory variables, systemic involvement, and treatment patterns were compared between groups. Binary logistic regression analyses were performed to evaluate the independent association between anti-Ro52 positivity and ILD. Other between-group comparisons were considered exploratory and were adjusted for multiple testing using the Benjamini-Hochberg false discovery rate (FDR) procedure. Of the 205 patients, 101 (49.3%) were anti-Ro52 positive and 104 (50.7%) were anti-Ro52 negative. ILD was more frequent in anti-Ro52-positive patients than in anti-Ro52-negative patients (27.7% vs. 10.6%, p = 0.003). In univariable analysis, anti-Ro52 positivity was associated with ILD (OR 3.24, 95% CI 1.51–6.95, p = 0.002). This association remained significant after adjustment for age, sex, smoking status, and disease duration (adjusted OR 3.61, 95% CI 1.64–7.96, p = 0.001), and after further adjustment for anti-SSA positivity (adjusted OR 4.48, 95% CI 1.86–10.81, p < 0.001). Anti-Ro52-positive patients also had higher frequencies of anti-SSA positivity, anti-SSB positivity, and a speckled ANA pattern after FDR correction. Anti-Ro52 positivity was associated with a higher frequency of ILD and a distinct serological profile in SjD. These findings support its potential value in clinical phenotyping, although prospective multicenter studies are needed for validation.
- 31 August 2026
- Published by Springer Nature in Clinical and Experimental Medicine
Open AccessAssociation of anti-Ro52 antibody positivity with interstitial lung disease and serological features in primary Sjögren’s disease
To investigate the association of anti-Ro52 antibody positivity with interstitial lung disease (ILD), serological findings, clinical manifestations, and treatment patterns in patients with primary Sjögren’s disease (SjD). This retrospective cross-sectional study included 205 patients with SjD. Patients were classified as anti-Ro52-positive or anti-Ro52-negative. Demographic features, clinical findings, laboratory variables, systemic involvement, and treatment patterns were compared between groups. Binary logistic regression analyses were performed to evaluate the independent association between anti-Ro52 positivity and ILD. Other between-group comparisons were considered exploratory and were adjusted for multiple testing using the Benjamini-Hochberg false discovery rate (FDR) procedure. Of the 205 patients, 101 (49.3%) were anti-Ro52 positive and 104 (50.7%) were anti-Ro52 negative. ILD was more frequent in anti-Ro52-positive patients than in anti-Ro52-negative patients (27.7% vs. 10.6%, p = 0.003). In univariable analysis, anti-Ro52 positivity was associated with ILD (OR 3.24, 95% CI 1.51–6.95, p = 0.002). This association remained significant after adjustment for age, sex, smoking status, and disease duration (adjusted OR 3.61, 95% CI 1.64–7.96, p = 0.001), and after further adjustment for anti-SSA positivity (adjusted OR 4.48, 95% CI 1.86–10.81, p < 0.001). Anti-Ro52-positive patients also had higher frequencies of anti-SSA positivity, anti-SSB positivity, and a speckled ANA pattern after FDR correction. Anti-Ro52 positivity was associated with a higher frequency of ILD and a distinct serological profile in SjD. These findings support its potential value in clinical phenotyping, although prospective multicenter studies are needed for validation.
- Open Access
RETRACTED: Kaya et al. The Superiority of Compressed Colchicine Tablets over Coated Colchicine Tablets for Familial Mediterranean Fever. Medicina 2024, 60, 1728
The Journal retracts the article “The Superiority of Compressed Colchicine Tablets Over Coated Colchicine Tablets for Familial Mediterranean Fever”
Open AccessRETRACTED: Kaya et al. The Superiority of Compressed Colchicine Tablets over Coated Colchicine Tablets for Familial Mediterranean Fever. Medicina 2024, 60, 1728
The Journal retracts the article “The Superiority of Compressed Colchicine Tablets Over Coated Colchicine Tablets for Familial Mediterranean Fever”
- 21 November 2024
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 18 (24) , 1093-1102
Immune nutrition indices are associated with disease activity in rheumatoid arthritis: a cross-sectional study
This study aimed to evaluate the relationship between immune nutrition indices and disease activity in rheumatoid arthritis (RA). The current study included a cross-sectional analysis of 90 age and gender-matched healthy controls and 116 RA patients who satisfied the 2010 American College of Rheumatology and European League Against Rheumatism categorization criteria. Patients were categorized into remission (disease activity score 28- erythrocyte sedimentation rate (DAS 28-ESR) p < 0.001). The clinical and simplified disease activity index, DAS 28-ESR had negative correlation with PNI and CALLY (p < 0.001). PNI and CALLY were independently related markers of disease activity (p < 0.001) by regression analysis. According to receiver operating characteristic curve analysis, the ideal cutoff values for the active disease are as follows: CONUT, 0.5; CALLY, 12.5, SII, 579.43, FAR, 90.43, and PNI, 40. CALLY was the most sensitive (84.06%) and specific marker (95.74%). CALLY and PNI may be useful prognostic markers for assessing disease activity in RA patients.
- 21 November 2024
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 18 (24) , 1093-1102
Immune nutrition indices are associated with disease activity in rheumatoid arthritis: a cross-sectional study
This study aimed to evaluate the relationship between immune nutrition indices and disease activity in rheumatoid arthritis (RA). The current study included a cross-sectional analysis of 90 age and gender-matched healthy controls and 116 RA patients who satisfied the 2010 American College of Rheumatology and European League Against Rheumatism categorization criteria. Patients were categorized into remission (disease activity score 28- erythrocyte sedimentation rate (DAS 28-ESR) p < 0.001). The clinical and simplified disease activity index, DAS 28-ESR had negative correlation with PNI and CALLY (p < 0.001). PNI and CALLY were independently related markers of disease activity (p < 0.001) by regression analysis. According to receiver operating characteristic curve analysis, the ideal cutoff values for the active disease are as follows: CONUT, 0.5; CALLY, 12.5, SII, 579.43, FAR, 90.43, and PNI, 40. CALLY was the most sensitive (84.06%) and specific marker (95.74%). CALLY and PNI may be useful prognostic markers for assessing disease activity in RA patients.
- Open Access
- 20 November 2024
- Published by BMJ in Lupus Science & Medicine
- Vol. 11 (2) , e001402
Role of intravenous immunoglobulins in the management of systemic lupus erythematosus: a single-centre experience
Objectives: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown aetiology that can affect almost any organ in the body. Although there are no specific guidelines for the use of intravenous immunoglobulin (IG) in the treatment of patients with SLE, it is thought to be an effective treatment. Our study aimed to evaluate the effectiveness and safety of intravenous IG and to describe the possible profile of patients with SLE who are candidates for intravenous IG treatment.Methods: This study was designed to retrospectively analyse patients with SLE treated with 2 g/kg/month of intravenous IG (divided across 5 consecutive days). We collected demographic, clinical, laboratory and treatment data from the patient files. The side effects of the intravenous IG treatment, changes in the immunosuppressive therapy used and changes in the clinical and laboratory parameters after the intravenous IG treatment were evaluated.Results: This study included 31 patients with SLE. The main indication for intravenous IG treatment was haematological involvement (20, 64.5%) and thrombocytopenia in particular (8, 25.8%). Intravenous IG was initiated mainly for refractory disease. At the end of the treatment, the acute phase values, proteinuria, complement levels and anti-double-stranded DNA decreased significantly (p<0.001). In most cases, the side effects were mild and usually manifested as myalgia or a fever.Conclusion: Despite its high cost, intravenous IG has demonstrated effectiveness in treating refractory SLE, especially when there is haematological involvement. Specific clinical features at baseline may identify the patients who are more likely to respond to this therapy.
- 20 November 2024
- Published by BMJ in Lupus Science & Medicine
- Vol. 11 (2) , e001402
Open AccessRole of intravenous immunoglobulins in the management of systemic lupus erythematosus: a single-centre experience
Objectives: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown aetiology that can affect almost any organ in the body. Although there are no specific guidelines for the use of intravenous immunoglobulin (IG) in the treatment of patients with SLE, it is thought to be an effective treatment. Our study aimed to evaluate the effectiveness and safety of intravenous IG and to describe the possible profile of patients with SLE who are candidates for intravenous IG treatment.Methods: This study was designed to retrospectively analyse patients with SLE treated with 2 g/kg/month of intravenous IG (divided across 5 consecutive days). We collected demographic, clinical, laboratory and treatment data from the patient files. The side effects of the intravenous IG treatment, changes in the immunosuppressive therapy used and changes in the clinical and laboratory parameters after the intravenous IG treatment were evaluated.Results: This study included 31 patients with SLE. The main indication for intravenous IG treatment was haematological involvement (20, 64.5%) and thrombocytopenia in particular (8, 25.8%). Intravenous IG was initiated mainly for refractory disease. At the end of the treatment, the acute phase values, proteinuria, complement levels and anti-double-stranded DNA decreased significantly (p<0.001). In most cases, the side effects were mild and usually manifested as myalgia or a fever.Conclusion: Despite its high cost, intravenous IG has demonstrated effectiveness in treating refractory SLE, especially when there is haematological involvement. Specific clinical features at baseline may identify the patients who are more likely to respond to this therapy.
- Open Access
RETRACTED: The Superiority of Compressed Colchicine Tablets over Coated Colchicine Tablets for Familial Mediterranean Fever
Background and Objectives: Familial Mediterranean fever (FMF) is an inherited autoinflammatory disease characterized by recurrent febrile attacks and serosal inflammation. The goals of FMF treatment are to prevent acute attacks and the development of amyloidosis. This study aimed to investigate the benefit of switching to compressed colchicine tablets in patients with FMF who are resistant or intolerant to the pharmaceutical preparation of coated colchicine tablets in terms of attack frequency and side effects. Materials and Methods: Patients who developed resistance and intolerance under coated colchicine tablet treatment and, therefore, switched to compressed colchicine tablets were identified. The attack frequencies and drug-related side effects in patients using the two different pharmaceutical colchicine preparations were compared. Results: The mean age of the 172 patients treated with compressed tablets alone following coated tablets was 36.3 ± 11.4 years, and 75 (43.6%) were male. The most common genetic mutation was detected as M694V in 111 (64.5%) patients, and 36 (20.9%) of them were homozygous. A decrease in the daily colchicine dose was found after switching to compressed colchicine tablets in patients followed for 7 years (2.1 ± 0.7 mg vs. 1.7 ± 0.5 mg; p < 0.001). Episodes lasted for one to three days and then resolved spontaneously. After treatment with the compressed tablet form of colchicine, 129 (75%), 33 (19%), and 10 (6%) patients had 0–3, 4–6, and more than 7 attacks, respectively (p < 0.001). Diarrhea and aminotransferase elevation, the most common side effects in patients using coated colchicine tablets, decreased after using compressed colchicine tablets (p < 0.001). Conclusions: Compressed colchicine tablets were shown to be effective in patients who did not respond to coated colchicine therapy and those with pre-treatment intolerance to biological agents.
Open AccessRETRACTED: The Superiority of Compressed Colchicine Tablets over Coated Colchicine Tablets for Familial Mediterranean Fever
Background and Objectives: Familial Mediterranean fever (FMF) is an inherited autoinflammatory disease characterized by recurrent febrile attacks and serosal inflammation. The goals of FMF treatment are to prevent acute attacks and the development of amyloidosis. This study aimed to investigate the benefit of switching to compressed colchicine tablets in patients with FMF who are resistant or intolerant to the pharmaceutical preparation of coated colchicine tablets in terms of attack frequency and side effects. Materials and Methods: Patients who developed resistance and intolerance under coated colchicine tablet treatment and, therefore, switched to compressed colchicine tablets were identified. The attack frequencies and drug-related side effects in patients using the two different pharmaceutical colchicine preparations were compared. Results: The mean age of the 172 patients treated with compressed tablets alone following coated tablets was 36.3 ± 11.4 years, and 75 (43.6%) were male. The most common genetic mutation was detected as M694V in 111 (64.5%) patients, and 36 (20.9%) of them were homozygous. A decrease in the daily colchicine dose was found after switching to compressed colchicine tablets in patients followed for 7 years (2.1 ± 0.7 mg vs. 1.7 ± 0.5 mg; p < 0.001). Episodes lasted for one to three days and then resolved spontaneously. After treatment with the compressed tablet form of colchicine, 129 (75%), 33 (19%), and 10 (6%) patients had 0–3, 4–6, and more than 7 attacks, respectively (p < 0.001). Diarrhea and aminotransferase elevation, the most common side effects in patients using coated colchicine tablets, decreased after using compressed colchicine tablets (p < 0.001). Conclusions: Compressed colchicine tablets were shown to be effective in patients who did not respond to coated colchicine therapy and those with pre-treatment intolerance to biological agents.
- 17 July 2019
- Published by Galenos Yayinevi in Turkish Journal of Osteoporosis
- Vol. 25 (2) , 53-57
Investigation of Short-wave Diathermy Genotoxic Effect in Patients with Knee Osteoarthritis
- 17 July 2019
- Published by Galenos Yayinevi in Turkish Journal of Osteoporosis
- Vol. 25 (2) , 53-57
Investigation of Short-wave Diathermy Genotoxic Effect in Patients with Knee Osteoarthritis